Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT-017 in PSMA-Positive mCRPC
NCT07798778Phase 1Recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SRT-017 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Percentage of Participants With Confirmed PSA Response (>=50% PSA Decline) at 12 weeks and Incidence of Adverse Events at 12 weeks. Started Jul 2026; status: recruiting.
02
Drugs
SRT-017
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07798778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07798778.